Jazz Pharmaceuticals plc Quarterly Income Statements Chart
Quarterly
|
Annual
Jazz Pharmaceuticals plc Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 | 2007-09-30 | 2007-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product sales | 985,571,000 | 839,418,000 | 1,025,211,000 | 989,707,000 | 964,144,000 | 842,102,000 | 967,339,000 | 938,398,000 | 946,987,000 | 884,219,000 | 967,526,000 | 935,766,000 | 928,300,000 | 809,837,000 | 892,883,000 | 834,247,000 | 748,340,000 | 603,531,000 | 661,303,000 | 596,949,000 | 558,203,000 | 530,205,000 | 576,526,000 | 532,321,000 | 523,423,000 | 503,331,000 | 467,334,000 | 465,197,000 | 496,095,000 | 440,847,000 | 407,971,000 | 389,655,000 | 373,678,000 | 371,621,000 | 379,110,000 | 333,916,000 | 338,924,000 | 338,754,000 | 332,106,000 | 307,035,000 | 304,407,000 | 289,100,000 | 244,986,000 | 233,796,000 | 230,386,000 | 206,564,000 | 194,652,000 | 181,942,000 | 174,130,000 | 128,310,000 | 107,336,000 | 80,935,000 | 72,216,000 | 63,464,000 | 49,903,000 | 52,357,000 | 43,838,000 | 39,528,000 | 34,283,000 | 37,319,000 | 29,992,000 | 26,478,000 | 21,319,000 | 18,880,000 | 17,022,000 | 14,751,000 | 13,984,000 | 14,860,000 | 13,436,000 | 13,615,000 |
| royalties and contract revenues | 60,141,000 | 58,423,000 | 62,962,000 | 65,262,000 | 59,681,000 | 59,881,000 | 44,596,000 | 33,742,000 | 10,330,000 | 8,593,000 | 4,597,000 | 4,886,000 | 4,578,000 | 3,884,000 | 3,848,000 | 3,868,000 | 3,471,000 | 4,050,000 | 4,214,000 | 3,939,000 | 4,233,000 | 4,521,000 | 5,214,000 | 5,381,000 | 10,710,000 | 4,855,000 | 9,123,000 | 4,176,000 | 4,384,000 | 3,766,000 | 3,884,000 | 4,731,000 | 2,375,000 | 2,560,000 | 2,051,000 | 2,094,000 | 1,957,000 | 2,118,000 | 1,641,000 | 2,268,000 | 2,177,000 | 2,130,000 | 1,933,000 | 1,978,000 | 1,774,000 | 1,688,000 | 1,585,000 | 1,761,000 | 1,385,000 | 1,229,000 | 1,078,000 | |||||||||||||||||||
| total revenues | 1,045,712,000 | 897,841,000 | 1,088,173,000 | 1,054,969,000 | 1,023,825,000 | 901,983,000 | 1,011,935,000 | 972,140,000 | 957,317,000 | 892,812,000 | 972,123,000 | 940,652,000 | 932,878,000 | 813,721,000 | 896,731,000 | 838,115,000 | 751,811,000 | 607,581,000 | 665,517,000 | 600,888,000 | 562,436,000 | 534,726,000 | 581,740,000 | 537,702,000 | 534,133,000 | 508,186,000 | 476,457,000 | 469,373,000 | 500,479,000 | 444,613,000 | 411,855,000 | 394,386,000 | 376,053,000 | 374,181,000 | 381,161,000 | 336,010,000 | 340,881,000 | 340,872,000 | 333,747,000 | 309,303,000 | 306,584,000 | 291,230,000 | 246,919,000 | 235,774,000 | 232,160,000 | 208,252,000 | 196,237,000 | 183,703,000 | 175,515,000 | 129,539,000 | 108,414,000 | 83,536,000 | 73,293,000 | 64,567,000 | 50,881,000 | 53,369,000 | 44,753,000 | 40,486,000 | 35,173,000 | 38,284,000 | 30,809,000 | 37,280,000 | 22,076,000 | 19,595,000 | 17,746,000 | 15,539,000 | 14,634,000 | 15,477,000 | 21,474,000 | 14,264,000 |
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of product sales | 116,268,000 | 104,620,000 | 128,713,000 | 111,611,000 | 109,902,000 | 95,487,000 | 107,243,000 | 102,153,000 | 97,537,000 | 128,644,000 | 167,364,000 | 133,661,000 | 124,208,000 | 115,284,000 | 136,153,000 | 145,224,000 | 119,194,000 | 40,189,000 | 50,157,000 | 42,095,000 | 28,008,000 | 28,657,000 | 35,348,000 | 31,400,000 | 27,676,000 | 33,506,000 | 26,337,000 | 26,574,000 | 34,714,000 | 33,919,000 | 31,203,000 | 28,672,000 | 25,065,000 | 24,311,000 | 23,980,000 | 23,439,000 | 24,030,000 | 28,385,000 | 21,813,000 | 28,298,000 | 26,994,000 | 30,692,000 | 30,924,000 | 25,643,000 | 24,252,000 | 25,031,000 | 27,220,000 | 25,763,000 | 32,629,000 | 15,370,000 | 10,758,000 | 3,862,000 | 3,901,000 | 3,370,000 | 2,809,000 | 4,784,000 | 3,091,000 | 2,802,000 | 2,882,000 | 2,782,000 | 2,338,000 | 2,575,000 | 1,943,000 | 3,305,000 | 5,525,000 | 2,796,000 | 2,298,000 | 3,283,000 | 1,938,000 | 1,679,000 |
| selling, general and administrative | 358,399,000 | 514,013,000 | 369,287,000 | 325,772,000 | 338,523,000 | 351,712,000 | 396,034,000 | 308,310,000 | 340,844,000 | 297,917,000 | 383,203,000 | 358,478,000 | 366,473,000 | 308,813,000 | 398,462,000 | 363,682,000 | 429,031,000 | 260,508,000 | 247,172,000 | 207,255,000 | 191,406,000 | 208,400,000 | 214,275,000 | 178,706,000 | 176,014,000 | 167,947,000 | 161,865,000 | 155,873,000 | 158,579,000 | 207,213,000 | 124,523,000 | 132,328,000 | 144,255,000 | 124,368,000 | 122,618,000 | 128,765,000 | 125,555,000 | 104,044,000 | 107,132,000 | 112,388,000 | 93,501,000 | 100,556,000 | 106,363,000 | 81,299,000 | 74,970,000 | 77,506,000 | 70,528,000 | 61,377,000 | 60,924,000 | 60,638,000 | 46,999,000 | 36,384,000 | 30,547,000 | 22,094,000 | 19,911,000 | 17,070,000 | 18,040,000 | 17,096,000 | 16,790,000 | 15,718,000 | 15,061,000 | 13,657,000 | 14,216,000 | 20,183,000 | 24,329,000 | 34,109,000 | 32,780,000 | 27,957,000 | 18,069,000 | 18,175,000 |
| research and development | 189,972,000 | 180,652,000 | 240,500,000 | 199,919,000 | 220,734,000 | 222,847,000 | 216,608,000 | 234,402,000 | 209,238,000 | 189,410,000 | 172,555,000 | 148,870,000 | 139,047,000 | 129,981,000 | 155,443,000 | 141,036,000 | 132,696,000 | 76,573,000 | 91,699,000 | 78,647,000 | 78,922,000 | 86,107,000 | 97,382,000 | 79,855,000 | 62,384,000 | 60,105,000 | 56,657,000 | 51,160,000 | 56,132,000 | 62,667,000 | 47,362,000 | 40,157,000 | 44,928,000 | 47,796,000 | 39,091,000 | 31,252,000 | 29,455,000 | 50,784,000 | 27,833,000 | 27,181,000 | 22,423,000 | 20,090,000 | 18,109,000 | 13,809,000 | 12,814,000 | 9,250,000 | 10,747,000 | 7,277,000 | 6,920,000 | 2,321,000 | 3,959,000 | 3,764,000 | 3,279,000 | 3,382,000 | 3,695,000 | 4,118,000 | 7,317,000 | 7,962,000 | 6,215,000 | 6,317,000 | 7,644,000 | 11,192,000 | 11,408,000 | 14,689,000 | 12,149,000 | 21,882,000 | 21,243,000 | 20,540,000 | 16,978,000 | 17,407,000 |
| intangible asset amortization | 162,103,000 | 154,448,000 | 158,903,000 | 157,457,000 | 155,223,000 | 155,730,000 | 151,553,000 | 154,883,000 | 152,062,000 | 149,786,000 | 137,387,000 | 141,232,000 | 148,456,000 | 172,094,000 | 157,293,000 | 159,804,000 | 140,480,000 | 68,192,000 | 67,075,000 | 66,684,000 | 62,974,000 | 62,847,000 | 173,490,000 | 62,863,000 | 61,576,000 | 56,885,000 | 46,543,000 | 46,989,000 | 54,959,000 | 53,007,000 | 47,313,000 | 26,186,000 | 25,665,000 | 26,453,000 | 26,737,000 | 22,642,000 | 23,690,000 | 26,127,000 | 23,668,000 | 24,677,000 | 30,630,000 | 32,795,000 | 31,182,000 | 20,524,000 | 19,564,000 | 19,399,000 | 19,555,000 | 21,907,000 | 19,742,000 | 15,751,000 | 13,513,000 | 1,862,000 | 1,862,000 | 1,862,000 | 1,862,000 | 1,862,000 | 1,862,000 | 2,044,000 | 2,057,000 | |||||||||||
| acquired in-process research and development | 905,362,000 | 10,000,000 | 18,000,000 | 1,000,000 | 375,000,000 | 69,148,000 | 36,000,000 | 10,000,000 | 3,000,000 | 202,250,000 | 51,775,000 | 2,200,000 | 56,000,000 | 75,000,000 | 2,000,000 | 15,000,000 | 8,750,000 | 75,000,000 | 127,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 1,732,104,000 | 953,733,000 | 897,403,000 | 794,759,000 | 824,382,000 | 835,776,000 | 889,438,000 | 799,748,000 | 799,681,000 | 766,757,000 | 1,235,509,000 | 915,889,000 | 847,332,000 | 726,172,000 | 847,351,000 | 809,746,000 | 821,401,000 | 445,462,000 | 492,103,000 | 404,681,000 | 364,310,000 | 724,400,000 | 520,495,000 | 404,599,000 | 329,850,000 | 374,443,000 | 291,402,000 | 280,596,000 | 347,280,000 | 356,806,000 | 325,401,000 | 229,343,000 | 239,913,000 | 237,928,000 | 212,426,000 | 214,848,000 | 234,253,000 | 209,340,000 | 180,446,000 | 192,544,000 | 248,548,000 | 216,939,000 | 313,578,000 | 141,275,000 | 131,600,000 | 131,186,000 | 128,050,000 | 116,324,000 | 120,215,000 | 94,080,000 | 75,229,000 | 45,872,000 | 39,589,000 | 30,708,000 | 28,277,000 | 27,834,000 | 30,310,000 | 29,904,000 | 27,944,000 | 26,874,000 | 27,100,000 | 29,246,000 | 29,299,000 | 71,314,000 | 45,490,000 | 62,633,000 | 58,442,000 | 74,221,000 | 39,272,000 | 57,017,000 |
| income from operations | -686,392,000 | -55,892,000 | 190,770,000 | 260,210,000 | 199,443,000 | 66,207,000 | 122,497,000 | 172,392,000 | 157,636,000 | 126,055,000 | -263,386,000 | 24,763,000 | 85,546,000 | 87,549,000 | 49,380,000 | 28,369,000 | -69,590,000 | 162,119,000 | 173,414,000 | 196,207,000 | 198,126,000 | -189,674,000 | 61,245,000 | 133,103,000 | 204,283,000 | 133,743,000 | 185,055,000 | 188,777,000 | 153,199,000 | 87,807,000 | 86,454,000 | 165,043,000 | 136,140,000 | 136,253,000 | 168,735,000 | 121,162,000 | 106,628,000 | 131,532,000 | 153,301,000 | 116,759,000 | 58,036,000 | 74,291,000 | -66,659,000 | 94,499,000 | 100,560,000 | 77,066,000 | 68,187,000 | 67,379,000 | 55,300,000 | 35,459,000 | 33,185,000 | 37,664,000 | 33,704,000 | 33,859,000 | 22,604,000 | 25,535,000 | 14,443,000 | 10,582,000 | 7,229,000 | 11,410,000 | 3,709,000 | 8,034,000 | -7,223,000 | -51,719,000 | -27,744,000 | -47,094,000 | -43,808,000 | -58,744,000 | -17,798,000 | -42,753,000 |
| yoy | -444.15% | -184.42% | 55.73% | 50.94% | 26.52% | -47.48% | -146.51% | 596.17% | 84.27% | 43.98% | -633.39% | -12.71% | -222.93% | -46.00% | -71.52% | -85.54% | -135.12% | -185.47% | 183.15% | 47.41% | -3.01% | -241.82% | -66.90% | -29.49% | 33.34% | 52.31% | 114.05% | 14.38% | 12.53% | -35.56% | -48.76% | 36.22% | 27.68% | 3.59% | 10.07% | 3.77% | 83.73% | 77.05% | -329.98% | 23.56% | -42.29% | -3.60% | -197.76% | 40.25% | 81.84% | 117.34% | 105.48% | 78.89% | 64.08% | 4.73% | 46.81% | 47.50% | 133.36% | 219.97% | 212.69% | 123.79% | 289.40% | 31.72% | -200.08% | -122.06% | -113.37% | -117.06% | -83.51% | -11.96% | 55.88% | 10.15% | ||||
| qoq | 1128.07% | -129.30% | -26.69% | 30.47% | 201.24% | -45.95% | -28.94% | 9.36% | 25.05% | -147.86% | -1163.63% | -71.05% | -2.29% | 77.30% | 74.06% | -140.77% | -142.93% | -6.51% | -11.62% | -0.97% | -204.46% | -409.70% | -53.99% | -34.84% | 52.74% | -27.73% | -1.97% | 23.22% | 74.47% | 1.56% | -47.62% | 21.23% | -0.08% | -19.25% | 39.26% | 13.63% | -18.93% | -14.20% | 31.30% | 101.18% | -21.88% | -211.45% | -170.54% | -6.03% | 30.49% | 13.02% | 1.20% | 21.84% | 55.95% | 6.85% | -11.89% | 11.75% | -0.46% | 49.79% | -11.48% | 76.80% | 36.49% | 46.38% | -36.64% | 207.63% | -53.83% | -211.23% | -86.03% | 86.42% | -41.09% | 7.50% | -25.43% | 230.06% | -58.37% | |
| operating margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -47,363,000 | -53,706,000 | -51,256,000 | -58,702,000 | -62,023,000 | -66,116,000 | -70,324,000 | -71,497,000 | -73,470,000 | -74,147,000 | -74,125,000 | -80,244,000 | -63,189,000 | -70,684,000 | -88,598,000 | -93,372,000 | -69,420,000 | -27,376,000 | -27,573,000 | -27,428,000 | -26,210,000 | -18,496,000 | -18,244,000 | -17,861,000 | -18,234,000 | -17,922,000 | -17,904,000 | -18,920,000 | -19,646,000 | -20,605,000 | -19,192,000 | -18,294,000 | -18,844,000 | -18,498,000 | -12,121,000 | -12,192,000 | -12,210,000 | -12,650,000 | -15,812,000 | -16,245,000 | -14,530,000 | -11,429,000 | -10,076,000 | -6,173,000 | -6,202,000 | -7,142,000 | -7,670,000 | -7,750,000 | -1,481,000 | -58,000 | -110,000 | -129,000 | -659,000 | -777,000 | -1,077,000 | -1,197,000 | -4,687,000 | -5,767,000 | -5,762,000 | -5,384,000 | -5,856,000 | -5,794,000 | -5,365,000 | -5,355,000 | -5,235,000 | -3,787,000 | -3,554,000 | -3,511,000 | -3,314,000 | |
| foreign exchange gain | -1,799,000 | 507,000 | -1,693,000 | -2,382,000 | 3,193,000 | -4,133,000 | -4,649,000 | -1,343,000 | -10,540,000 | 315,500 | -2,631,000 | 2,950,000 | 943,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax benefit and equity in loss of investees | -735,554,000 | 137,927,000 | -1,602,000 | 81,784,000 | 55,101,000 | 144,805,000 | 168,140,000 | 171,452,000 | 40,767,000 | 114,209,000 | 184,116,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | -17,170,000 | -57,912,000 | -14,533,000 | -30,653,000 | 11,669,000 | -33,089,000 | -47,176,000 | -24,323,000 | -15,324,000 | -100,042,000 | -43,027,000 | -16,112,000 | -12,467,000 | -18,057,000 | 18,019,000 | 10,767,000 | 19,283,000 | 54,754,000 | -51,287,000 | -34,523,000 | 10,903,000 | -78,650,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| equity in loss of investees | 86,000 | 542,000 | 12,000 | 1,347,000 | 1,669,000 | 1,005,000 | 624,000 | 623,000 | 1,897,000 | 1,298,000 | 1,030,000 | 868,000 | 893,000 | 843,000 | 437,000 | 586,000 | 337,000 | 273,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | -718,470,000 | -92,541,000 | 191,115,000 | 215,055,000 | 168,568,000 | -14,618,000 | 94,154,000 | 146,820,000 | 104,438,000 | 69,420,000 | -240,724,000 | -19,648,000 | 34,665,000 | 1,647,000 | -35,351,000 | -52,833,000 | -363,316,000 | 121,832,000 | 133,414,000 | 148,234,000 | 114,801,000 | -157,833,000 | 73,992,000 | 102,276,000 | 261,898,000 | 85,201,000 | 159,470,000 | 149,316,000 | 92,321,000 | 45,991,000 | 63,526,000 | 105,604,000 | 86,511,000 | 87,145,000 | 111,282,000 | 74,121,000 | 82,761,000 | 87,960,000 | 88,113,000 | 70,700,000 | 25,768,000 | 43,586,000 | -93,639,000 | 55,293,000 | 75,409,000 | 42,185,000 | 43,425,000 | 200,551,000 | 33,209,000 | 27,145,000 | 27,681,000 | 37,473,000 | 32,482,000 | 33,202,000 | 21,827,000 | 24,459,000 | 13,243,000 | -6,388,000 | 1,464,000 | 5,653,000 | -1,672,000 | 2,171,000 | -12,988,000 | -56,940,000 | -28,809,000 | -51,880,000 | -46,710,000 | -60,020,000 | -19,359,000 | -39,863,000 |
| yoy | -526.22% | 533.06% | 102.98% | 46.48% | 61.40% | -121.06% | -139.11% | -847.25% | 201.28% | 4114.94% | 580.95% | -62.81% | -109.54% | -98.65% | -126.50% | -135.64% | -416.47% | -177.19% | 80.31% | 44.94% | -56.17% | -285.25% | -53.60% | -31.50% | 183.68% | 85.26% | 151.03% | 41.39% | 6.72% | -47.22% | -42.91% | 42.48% | 4.53% | -0.93% | 26.29% | 4.84% | 221.18% | 101.81% | -194.10% | 27.86% | -65.83% | 3.32% | -315.63% | -72.43% | 127.07% | 55.41% | 56.88% | 435.19% | 2.24% | -18.24% | 26.82% | 53.21% | 145.28% | -619.76% | 1390.92% | 332.67% | -892.05% | -394.24% | -111.27% | -109.93% | -94.20% | -104.18% | -72.19% | -5.13% | 48.81% | 30.15% | ||||
| qoq | 676.38% | -148.42% | -11.13% | 27.58% | -1253.15% | -115.53% | -35.87% | 40.58% | 50.44% | -128.84% | 1125.18% | -156.68% | 2004.74% | -104.66% | -33.09% | -85.46% | -398.21% | -8.68% | -10.00% | 29.12% | -172.74% | -313.31% | -27.65% | -60.95% | 207.39% | -46.57% | 6.80% | 61.74% | 100.74% | -27.60% | -39.85% | 22.07% | -0.73% | -21.69% | 50.14% | -10.44% | -5.91% | -0.17% | 24.63% | 174.37% | -40.88% | -146.55% | -269.35% | -26.68% | 78.76% | -2.86% | -78.35% | 503.91% | 22.34% | -1.94% | -26.13% | 15.37% | -2.17% | 52.11% | -10.76% | 84.69% | -307.31% | -536.34% | -74.10% | -438.10% | -177.02% | -116.72% | -77.19% | 97.65% | -44.47% | 11.07% | -22.18% | 210.04% | -51.44% | |
| net income margin % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | -11,740 | 3,130 | 3,500 | 2,680 | -230 | 1,500 | 2,330 | 1,630 | 1,090 | -3,850 | -310 | 560 | 30 | -540 | -860 | -6,110 | 2,160 | 2,390 | 2,670 | 2,070 | -2,820 | 1,975 | 1,800 | 4,620 | 1,490 | 1,195 | 2,470 | 1,530 | 770 | 1,060 | 1,760 | 1,440 | 1,210 | 430 | 730 | -1,580 | 480 | 510 | 0.89 | 0.77 | 0.81 | 0.54 | 0.66 | 0.34 | -0.18 | 0.05 | 0.07 | |||||||||||||||||||||||
| diluted | -11,740 | 3,020 | 3,420 | 2,490 | -230 | 1,430 | 2,140 | 1,520 | 1,040 | -3,840 | -310 | 550 | 30 | -540 | -860 | -6,110 | 2,090 | 2,350 | 2,640 | 2,060 | -2,820 | 1,950 | 1,780 | 4,560 | 1,470 | 1,170 | 2,410 | 1,500 | 750 | 1,030 | 1,720 | 1,410 | 1,190 | 410 | 700 | -1,580 | 450 | 480 | 0.79 | 0.69 | 0.71 | 0.48 | 0.61 | 0.32 | -0.18 | 0.04 | 0.07 | |||||||||||||||||||||||
| weighted-average ordinary shares used in per share calculations - basic | 61,194 | 61,838 | 61,414 | 62,882 | 62,537 | 63,291 | 63,114 | 63,991 | 63,494 | 62,539 | 62,785 | 62,436 | 61,865 | 59,694 | 61,284 | 59,448 | 56,468 | 55,712 | 55,545 | 55,413 | 55,956 | 56,749 | 56,674 | 56,707 | 57,206 | 59,976 | 60,476 | 60,177 | 59,928 | 60,108 | 60,100 | 59,880 | 60,437 | 60,499 | 61,142 | |||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in per share calculations - diluted | 61,194 | 66,007 | 63,174 | 69,625 | 62,537 | 72,066 | 71,293 | 73,540 | 73,771 | 62,539 | 62,785 | 63,431 | 62,907 | 59,694 | 61,284 | 59,448 | 58,393 | 56,517 | 56,236 | 55,864 | 55,956 | 57,550 | 57,438 | 57,427 | 58,081 | 61,221 | 61,857 | 61,438 | 61,178 | 61,436 | 61,463 | 61,178 | 61,644 | 61,833 | 62,474 | |||||||||||||||||||||||||||||||||||
| foreign exchange loss | -213,000 | -471,750 | -701,000 | -141,500 | -1,377,000 | -558,750 | -639,000 | -464,000 | -1,132,000 | -894,250 | -1,033,000 | -1,933,000 | -611,000 | -1,295,250 | -756,000 | -2,697,000 | -1,728,000 | -2,224,000 | -5,427,000 | -1,464,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax (benefit) expense and equity in loss of investees | -109,811,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -17,812,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -1,520 | -0.105 | -0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in per share calculations - basic and diluted | 60,979 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax benefit and equity in gain of investees | 84,283,000 | 200,807,000 | 59,100,750 | 99,518,000 | -8,197,750 | -60,130,000 | 21,014,000 | 135,686,000 | -209,302,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| equity in gain of investees | 411,000 | 285,000 | 637,000 | -126,000 | 2,287,000 | 2,545,000 | 2,461,000 | 4,142,000 | -4,165,000 | -182,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| impairment charge | 133,648,000 | 34,034,750 | 136,139,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense and equity in gain of investees | 6,325,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | 536,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax benefit and equity in (gain) loss of investees | -17,002,000 | -67,634,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| equity in (gain) loss of investees | -568,500 | 3,256,000 | -1,365,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision and equity in (gain) loss of investees | -136,060,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax provision | 228,621,000 | 29,116,000 | 18,754,500 | 19,348,000 | 36,524,000 | 19,146,000 | 1,239,000 | 35,515,000 | 29,160,000 | 29,120,000 | 45,332,000 | 34,030,000 | 23,162,750 | 29,945,000 | 30,647,000 | 32,059,000 | 24,221,000 | 19,350,000 | 17,027,000 | 14,893,500 | 18,335,000 | 23,605,000 | 17,634,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| impairment charges | 42,896,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment and modification of debt | -1,425,000 | -638,000 | -16,815,000 | -3,749,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision and equity in loss of investees | 115,210,000 | 91,001,500 | 169,101,000 | 129,431,000 | 65,474,000 | 65,038,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision and equity in loss of investee | 141,322,000 | 115,832,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| equity in loss of investee | 203,000 | 161,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| foreign currency loss | -749,000 | -969,000 | -614,000 | -385,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision and equity in loss of investee, net of tax | 116,368,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| equity in loss of investee, net of tax | 103,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to noncontrolling interests, net of tax | -1,000 | 2,000 | -73,000 | -989,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to jazz pharmaceuticals plc | 87,145,000 | 111,282,000 | 82,761,000 | 87,960,000 | 88,114,000 | 70,700,000 | 25,766,000 | 43,659,000 | -92,650,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to jazz pharmaceuticals plc per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 1,440 | 1,840 | 1,010 | 1,430 | 1,440 | 1,160 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 1,410 | 1,800 | 977.5 | 1,390 | 1,400 | 1,120 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| foreign currency gain | -819,000 | 2,091,000 | -977,000 | -1,914,000 | 2,245,000 | 6,483,000 | 74,000 | 123,000 | 271,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax provision | 156,614,000 | 108,151,000 | 84,856,000 | 117,905,000 | 118,760,000 | 102,759,000 | 49,989,000 | 62,936,000 | -76,612,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in per share calculation - basic | 61,232 | 61,435 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in per share calculation - diluted | 63,036 | 63,154 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in calculating net income attributable to jazz pharmaceuticals plc per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 61,190,000 | 60,803,000 | 60,305,000 | 59,519,000 | 58,526,000 | 58,298,000 | 58,217 | 58,737 | 58,358 | 56,643,000 | 57,703 | 56,952 | 53,923 | 41,499 | 42,028 | 41,209 | 40,362 | 36,343 | 38,965 | 35,423 | 31,412 | 29,021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 63,090,000 | 62,964,000 | 62,680,000 | 62,378,000 | 58,526,000 | 61,569,000 | 61,519 | 61,568 | 61,511 | 60,195,000 | 60,883 | 60,554 | 58,084 | 46,798 | 47,241 | 46,601 | 45,697 | 39,411 | 41,737 | 35,423 | 34,926 | 29,023 | ||||||||||||||||||||||||||||||||||||||||||||||||
| intangible asset impairment | 32,806,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per ordinary share attributable to jazz pharmaceuticals plc: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | -11,740 | 3,130 | 3,500 | 2,680 | -230 | 1,500 | 2,330 | 1,630 | 1,090 | -3,850 | -310 | 560 | 30 | -540 | -860 | -6,110 | 2,160 | 2,390 | 2,670 | 2,070 | -2,820 | 1,975 | 1,800 | 4,620 | 1,490 | 1,195 | 2,470 | 1,530 | 770 | 1,060 | 1,760 | 1,440 | 1,210 | 430 | 730 | -1,580 | 480 | 510 | 0.89 | 0.77 | 0.81 | 0.54 | 0.66 | 0.34 | -0.18 | 0.05 | 0.07 | |||||||||||||||||||||||
| diluted | -11,740 | 3,020 | 3,420 | 2,490 | -230 | 1,430 | 2,140 | 1,520 | 1,040 | -3,840 | -310 | 550 | 30 | -540 | -860 | -6,110 | 2,090 | 2,350 | 2,640 | 2,060 | -2,820 | 1,950 | 1,780 | 4,560 | 1,470 | 1,170 | 2,410 | 1,500 | 750 | 1,030 | 1,720 | 1,410 | 1,190 | 410 | 700 | -1,580 | 450 | 480 | 0.79 | 0.69 | 0.71 | 0.48 | 0.61 | 0.32 | -0.18 | 0.04 | 0.07 | |||||||||||||||||||||||
| weighted-average ordinary shares used in calculating net income per ordinary share attributable to jazz pharmaceuticals plc: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 61,190,000 | 60,803,000 | 60,305,000 | 59,519,000 | 58,526,000 | 58,298,000 | 58,217 | 58,737 | 58,358 | 56,643,000 | 57,703 | 56,952 | 53,923 | 41,499 | 42,028 | 41,209 | 40,362 | 36,343 | 38,965 | 35,423 | 31,412 | 29,021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 63,090,000 | 62,964,000 | 62,680,000 | 62,378,000 | 58,526,000 | 61,569,000 | 61,519 | 61,568 | 61,511 | 60,195,000 | 60,883 | 60,554 | 58,084 | 46,798 | 47,241 | 46,601 | 45,697 | 39,411 | 41,737 | 35,423 | 34,926 | 29,023 | ||||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations before income tax provision | 55,148,250 | 93,744,000 | 65,790,000 | 61,059,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations | 55,293,000 | 75,409,000 | 42,185,000 | 43,425,000 | 166,206,000 | 33,595,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from discontinued operations | 6,908,480 | -386,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic income per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted income per ordinary share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in per share computations: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 61,190,000 | 60,803,000 | 60,305,000 | 59,519,000 | 58,526,000 | 58,298,000 | 58,217 | 58,737 | 58,358 | 56,643,000 | 57,703 | 56,952 | 53,923 | 41,499 | 42,028 | 41,209 | 40,362 | 36,343 | 38,965 | 35,423 | 31,412 | 29,021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 63,090,000 | 62,964,000 | 62,680,000 | 62,378,000 | 58,526,000 | 61,569,000 | 61,519 | 61,568 | 61,511 | 60,195,000 | 60,883 | 60,554 | 58,084 | 46,798 | 47,241 | 46,601 | 45,697 | 39,411 | 41,737 | 35,423 | 34,926 | 29,023 | ||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | -7,399,000 | 1,000 | 1,000 | 1,000 | 2,000 | 2,000 | 5,000 | 2,000 | 6,000 | 21,000 | 134,000 | 353,000 | 450,000 | 897,000 | 1,582,000 | 1,969,000 | 1,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| foreign exchange and other | -339,250 | -1,099,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -150,000 | -1,097,000 | -12,287,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations before benefit from income tax expense | 29,977,250 | 46,451,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income tax expense | 6,241,500 | 12,856,000 | 6,593,000 | 5,517,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | -240,000 | -1,000 | -4,000 | 2,000 | 1,000 | -13,000 | 8,000 | 10,000 | 19,000 | -1,000 | -12,000 | -19,000 | -19,000 | 4,904,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit from income tax expense | 33,738,000 | 33,198,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average ordinary shares used in computing net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 61,190,000 | 60,803,000 | 60,305,000 | 59,519,000 | 58,526,000 | 58,298,000 | 58,217 | 58,737 | 58,358 | 56,643,000 | 57,703 | 56,952 | 53,923 | 41,499 | 42,028 | 41,209 | 40,362 | 36,343 | 38,965 | 35,423 | 31,412 | 29,021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 63,090,000 | 62,964,000 | 62,680,000 | 62,378,000 | 58,526,000 | 61,569,000 | 61,519 | 61,568 | 61,511 | 60,195,000 | 60,883 | 60,554 | 58,084 | 46,798 | 47,241 | 46,601 | 45,697 | 39,411 | 41,737 | 35,423 | 34,926 | 29,023 | ||||||||||||||||||||||||||||||||||||||||||||||||
| interest income and other | 71,000 | 69,000 | 4,000 | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| royalties | 576,000 | 792,000 | 819,000 | 693,000 | 728,000 | 630,000 | 674,000 | 605,000 | 681,000 | 532,000 | 518,000 | 472,000 | 431,000 | 440,000 | 503,000 | 365,000 | 332,000 | 253,000 | 360,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| contract revenues | 213,500 | 285,000 | 284,000 | 285,000 | 284,000 | 285,000 | 284,000 | 285,000 | 284,000 | 285,000 | 10,284,000 | 285,000 | 284,000 | 284,000 | 285,000 | 285,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.45 | -1.28 | -1.07 | -2.17 | -1.97 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | -11,740 | 3,130 | 3,500 | 2,680 | -230 | 1,500 | 2,330 | 1,630 | 1,090 | -3,850 | -310 | 560 | 30 | -540 | -860 | -6,110 | 2,160 | 2,390 | 2,670 | 2,070 | -2,820 | 1,975 | 1,800 | 4,620 | 1,490 | 1,195 | 2,470 | 1,530 | 770 | 1,060 | 1,760 | 1,440 | 1,210 | 430 | 730 | -1,580 | 480 | 510 | 0.89 | 0.77 | 0.81 | 0.54 | 0.66 | 0.34 | -0.18 | 0.05 | 0.07 | |||||||||||||||||||||||
| diluted | -11,740 | 3,020 | 3,420 | 2,490 | -230 | 1,430 | 2,140 | 1,520 | 1,040 | -3,840 | -310 | 550 | 30 | -540 | -860 | -6,110 | 2,090 | 2,350 | 2,640 | 2,060 | -2,820 | 1,950 | 1,780 | 4,560 | 1,470 | 1,170 | 2,410 | 1,500 | 750 | 1,030 | 1,720 | 1,410 | 1,190 | 410 | 700 | -1,580 | 450 | 480 | 0.79 | 0.69 | 0.71 | 0.48 | 0.61 | 0.32 | -0.18 | 0.04 | 0.07 | |||||||||||||||||||||||
| weighted-average common shares used in computing net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 61,190,000 | 60,803,000 | 60,305,000 | 59,519,000 | 58,526,000 | 58,298,000 | 58,217 | 58,737 | 58,358 | 56,643,000 | 57,703 | 56,952 | 53,923 | 41,499 | 42,028 | 41,209 | 40,362 | 36,343 | 38,965 | 35,423 | 31,412 | 29,021 | ||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 63,090,000 | 62,964,000 | 62,680,000 | 62,378,000 | 58,526,000 | 61,569,000 | 61,519 | 61,568 | 61,511 | 60,195,000 | 60,883 | 60,554 | 58,084 | 46,798 | 47,241 | 46,601 | 45,697 | 39,411 | 41,737 | 35,423 | 34,926 | 29,023 | ||||||||||||||||||||||||||||||||||||||||||||||||
| amortization of intangible assets | 1,402,750 | 2,057,000 | 1,822,000 | 1,732,000 | 2,363,500 | 3,487,000 | 3,846,000 | 2,121,000 | 1,734,000 | 2,287,000 | 2,287,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of product rights | 3,918,000 | 715,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.45 | -1.28 | -1.07 | -2.17 | -1.97 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -1,520 | -0.105 | -0.05 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares used in computing net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 30,895 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | -0.45 | -1.28 | -1.07 | -2.17 | -1.97 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares used in computing net income per share, basic and diluted | 30,018 | 28,925 | 26,994 | 23,858 | 23,743 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit from government settlement | 17,469,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract revenue | 2,581,500 | 7,785,000 | 289,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on extinguishment of development financing obligation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| beneficial conversion feature | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income attributable to common stockholders | -19,701,500 | -19,359,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income per share attributable to common stockholders, basic | -1.875 | -0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares used in computing income per share attributable to common stockholders, basic | 23,671 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income per share attributable to common stockholders, diluted | -1.875 | -0.82 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in computing income per share attributable to common stockholders, diluted | 2,626.25 | 23,671 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss attributable to common stockholders | -39,863,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss per share attributable to common stockholders, basic and diluted | -5.27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares used in computing loss per share attributable to common stockholders, basic and diluted | 25,646 | 13,829 | 7,561 |
We provide you with 20 years income statements for Jazz Pharmaceuticals plc stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Jazz Pharmaceuticals plc stock. Explore the full financial landscape of Jazz Pharmaceuticals plc stock with our expertly curated income statements.
The information provided in this report about Jazz Pharmaceuticals plc stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.